Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chuikyo Subcommittee Discusses Pros and Cons of "Generics Coefficient"
March 16, 2009
- Council Proposes Nat'l Project to Quickly Develop Unapproved Drugs
March 16, 2009
- Amended Hypertension Management GL Discussed at JHF Workshop
March 16, 2009
- 3 More National Medical Centers Publish Lists of Generics They Use
March 16, 2009
- Nippon Shinyaku Licenses Prulifloxacin to Lee's Pharma in China
March 16, 2009
- Studies on Ethnic Differences between Japan, China and South Korea Progress
March 16, 2009
- Teijin, Nissan Chemical License NTC-801 to BMS
March 16, 2009
- Cancer Treatment Using Unapproved Peptide Vaccine Applied for as Advanced Medical Technology
March 16, 2009
- Bristol-Myers to Promote Sprycel with Over 200 MRs
March 16, 2009
- More Objective Endpoints Needed for Allergic Rhinitis Treatments
March 16, 2009
- 2008 Ethical Drug Market in Japan Totaled ¥8,254.3 Bil. on NHI Price Basis: IMS
March 16, 2009
- R&D NEWS IN BRIEF
March 16, 2009
- Astellas Files Lawsuit against CVT
March 16, 2009
- Ortho-K Recommended for Approval
March 16, 2009
- Olmetec Remains No. 1 for 2nd Month Running on Both GP and HP Markets: Rep Track Survey
March 16, 2009
- Takara Bio to Launch Reagent to Prepare Human iPS Cells
March 16, 2009
- Nat'l Univ. Hospitals to Consider Joint Purchase of Drugs
March 16, 2009
- New Sales System May Adversely Affect Business in Short Term: Mr Yamada of Rohto
March 16, 2009
- BUSINESS NEWS IN BRIEF
March 16, 2009
- Diclofenac-Based OTC Drugs Recommended for Approval
March 16, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…